The distribution of body fat predicts the risk of coronary heart disease, and central obesity consistently has been shown to be a risk factor for coronary heart disease, whereas peripheral obesity (measured as high hip circumference) appears to protect against coronary heart disease. The importance of fat distribution with regard to the risk of venous thromboembolism (VTE), ie, deep venous thrombosis and pulmonary embolism, has not been evaluated. In a 10-year follow-up study of 56 014 middle-aged men and women, which included 641 verified incident events of VTE, we evaluated the risk of VTE according to different measurements of fat distribution in the body. Our results show that all measurements of obesity are positively associated with VTE in both sexes. We also showed that a higher hip circumference in normal-weight persons was associated with a higher risk for VTE, which is in contrast to studies on coronary heart disease. We found statistically significant positive associations between idiopathic (unprovoked) VTE and all measurements of obesity. The associations between VTE and the anthropometric measurements persisted after adjustment for hypertension, diabetes mellitus, or hypercholesterolemia, which shows that the effect of obesity was not mediated solely by these factors. See p 1850.
Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New
York Heart Association Class I/II Heart Failure Cardiac resynchronization therapy (CRT) has proved efficacious in New York Heart Association (NYHA) class III/IV heart failure (HF). This key echocardiographic study assessed the impact of CRT on structural and functional reverse remodeling in patients with NYHA class I/II HF. The REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial was a large, prospective, double-blind, controlled trial of CRT in patients with NYHA class I/II HF, a QRS Ն120 ms, left ventricular (LV) end-diastolic dimension Ն55 mm, and LV ejection fraction Յ40% who were randomly assigned to active therapy (CRT-on; nϭ419) or control (CRT-off; nϭ191). Doppler echocardiograms were recorded at baseline, before hospital discharge, and at 6 and 12 months. The present study showed that CRT in patients with NYHA class I/II HF who were already receiving optimal therapy with a ␤-blocker (95%), angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker (97%) resulted in LV reverse remodeling with favorable changes in LV volume, shape, and ejection fraction similar to those that occurred in patients in NYHA class III/IV; however, there were no accompanying changes in LV diastolic function, LV mass, or severity of mitral regurgitation. There was 3-fold greater LV reverse remodeling in patients with a nonischemic origin of HF than in those with an ischemic origin. Our findings have potentially important clinical implications in that CRT may delay or interrupt the natural disease progression of HF in these patients. This and ongoing studies may define an important therapeutic role for CRT in patients with NYHA class I/II, as well as class III/IV HF, especially those cases with a nonischemic cause. See p 1858.
Three-Year Outcomes After Sirolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease: Insights From the j-Cypher Registry
Despite the growing popularity of stenting unprotected left main coronary arteries with drug-eluting stents, long-term outcomes have not been assessed adequately. This large multicenter registry in Japan (the j-Cypher registry) compared the 3-year clinical outcomes of 582 patients undergoing percutaneous coronary intervention for unprotected left main coronary artery (ULMCA) lesions with those of 12 242 patients undergoing percutaneous coronary intervention for non-ULMCA lesions only. The influence of lesion location and bifurcation stenting strategy on clinical outcomes was also assessed in 476 patients whose ULMCA lesions were treated exclusively with sirolimus-eluting stents. The main findings of this study are as follows: (1) Percutaneous coronary intervention for ULMCA lesions was associated with a higher late mortality rate than for lesions located elsewhere, but this finding was mainly related to factors other than the left main being the treatment site; (2) sirolimus-eluting stent implantation in ostial/shaft left main lesions was associated with a better 3-year target-lesion revascularization rate than in distal bifurcation lesions; and (3) patients with ULMCA plus 3-vessel disease had poor long-term outcome in terms of coronary revascularization, stent thrombosis, and cardiac death. Therefore, although ULMCA stenting with a sirolimus-eluting stent is an attractive option, clinical outcomes are less satisfactory in patients who need bifurcation 2-stent treatment or who have extensive coronary artery disease outside the ULMCA. Consideration of the individual patient's risk stratification is important when selecting coronary revascularization strategies in patients with ULMCA disease. See p 1866.
Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Intravascular Ultrasound Substudy
In the prospective, multicenter Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, patients with ST-segment elevation myocardial infarction within 12 hours of symptom onset were randomized 3:1 to TAXUS EXPRESS paclitaxel-eluting stents or EXPRESS bare metal stents. The intravascular ultrasound substudy enrolled 464 patients with baseline and 13-month follow-up imaging at 36 centers. Paclitaxel-eluting compared with bare metal stents significantly reduced percent net volume obstruction (6.5% [first and third quartiles, 2.2% and 10.8%] versus 15.6% [first and third quartiles, 7.2% and 28.8]; PϽ0.0001) but also resulted in more late-acquired stent malapposition (29.6% versus 7.9%; Pϭ0.0005) resulting from positive vessel remodeling. Plaque and/or thrombus protrusion through stent struts was initially present in 70.4% of paclitaxeleluting stents and 64.8% of bare metal stents; all resolved during follow-up. New aneurysm formation, stent fracture, and subclinical thrombus were uncommon, although seen only in paclitaxel-eluting stents. The present data demonstrate a reduction in neointimal hyperplasia and restenosis in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents compared with bare metal stents. Long-term follow-up is required to establish 
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Glycome and Transcriptome Regulation of Vasculogenesis
Promotion of neovasculature holds the potential for ameliorating coronary artery disease. The TOPCARE-AMI (Transplantation Of Progenitor Cells And Regeneration Enhancement in Acute Myocardial Infarction) trial indicated that circulating endothelial progenitor cells could improve left ventricular ejection fraction in patients after myocardial infarction. Recent studies have demonstrated that embryonic stem cells can differentiate into functional endothelial cells through vasculogenesis, which results in functional improvement that arises from increased neovascularization. The harnessing of vasculogenesis has the potential to revolutionize regenerative medicine but is contingent on a means to regulate cellular differentiation. In the present study, we demonstrate that the glyco-microenvironment of the stem cell, specifically the sulfated heparan sulfate glycosaminoglycans, plays a critical role in facilitating vasculogenesis. We confirmed these findings in vivo in larval zebrafish, in which desulfation of heparan sulfate glycosaminoglycans resulted in impaired vascular development. The phenotype is rescued with exogenous sulfated heparan sulfate glycosaminoglycans. Finally, we identified several downstream pathways that may mediate the regulation of vasculogenesis by heparan sulfate glycosaminoglycans, including a novel FOXO3A/ 5-IGF2 signaling pathway. This study reveals the exciting potential of harnessing defined cellular glyco-microenvironments for directed differentiation of precursor cells into endothelial cells, leading to neovascularization. See p 1883.
Hyperhomocysteinemia Promotes Inflammatory Monocyte Generation and Accelerates Atherosclerosis in Transgenic Cystathionine ␤-Synthase-Deficient Mice
Hyperhomocysteinemia (HHcy) is an independent risk factor for cardiovascular diseases. In this study, we established novel disease models with severe HHcy and hypercholesterolemia in which the mouse cystathionine ␤-synthase (CBS) and apolipoprotein E (apoE) genes are deficient and an inducible human CBS or disease-relevant mutant CBS (S466L) transgene is introduced to circumvent the neonatal lethality of CBS deficiency (Tg-hCBS apoE Ϫ/Ϫ Cbs Ϫ/Ϫ or Tg-S466L Cbs Ϫ/Ϫ mice). First, we demonstrated that severe HHcy accelerated atherosclerosis and inflammatory monocyte/macrophage accumulation in the lesion and increased plasma tumor necrosis factor-␣ and monocyte chemoattractant protein-1 levels in Tg-hCBS apoE Ϫ/Ϫ Cbs Ϫ/Ϫ mice fed a high-fat diet. Thus, systemic inflammation possibly mediated the enhanced Ly-6C monocyte/macrophage accumulation in the lesion. We also found that severe HHcy induced Ly-6C hi and Ly-6C mid inflammatory monocyte subset expansion in the peripheral blood, spleen, and bone marrow in Tg-hCBS apoE
Cbs
Ϫ/Ϫ and Tg-S466L Cbs mice independently of hyperlipidemia. Furthermore, we discovered that L-homocysteine, but not L-cysteine, promoted Ly-6C hi monocyte subset survival and Ly-6C mid subset differentiation in cultured primary mouse splenocytes. Finally, we reported that Hcy-induced Ly-6C mid subset differentiation was abolished by superoxide dismutase/catalase or the NAD(P)H oxidase inhibitor apocynin. Taken together, these results show that HHcy selectively promoted Ly-6C monocyte subset differentiation and enhanced their accumulations in the lesion, contributing to accelerated atherosclerosis in HHcy. Thus, the present study provides important insights into HHcy-related cardiovascular disease. See p 1893.
␥-H2AX Foci as a Biomarker for Patient X-Ray Exposure in Pediatric Cardiac Catheterization: Are We Underestimating Radiation Risks?
Interventional cardiologists should be aware that x-ray doses to patients can be high, especially in cases of complex procedures involving extensive use of fluoroscopy and multiple cine runs. With respect to the x-ray-induced oncogenic risk, children undergoing a catheterization procedure, eg, for treatment of congenital heart disease, require special attention in view of their higher radiosensitivity and the fraction of the body irradiated. For some patients, cardiac catheterization procedures need to be repeated several times, leading to significant cumulative effective doses and cancer risks. In the present study, a biomarker approach (analysis of ␥-H2AX foci in lymphocytes) was used to assess DNA damage induced by interventional x-rays in a pediatric patient group. These patient data point to a low-dose hypersensitivity, resulting in risk estimates seriously higher than those obtained from the linearno-threshold hypothesis, generally used in radiation protection until now. Present data emphasize the importance of all measures, technical and procedural, for reducing and optimizing patient x-ray exposure. This applies also to the hybrid approach, which combines surgery and interventional techniques. The direct link between x-ray exposure and effects in patients observed in the present work should trigger the radiological awareness of interventional cardiologists. See p 1903.
High Levels of Acetylated Low-Density Lipoprotein Uptake and Low Tyrosine Kinase With Immunoglobulin and Epidermal Growth Factor Homology Domains-2 (Tie2) Promoter Activity Distinguish Sinusoids From Other Vessel Types in Murine Bone Marrow
Changes in the bone marrow microvasculature have been demonstrated to result from the presence of certain forms of leukemia in the bone marrow. Increases in the number of vascular cross sections within a given section of the bone marrow have been the primary method of demonstrating increases in marrow vascular density. Furthermore, antiangiogenic treatments have been used to treat hematologic malignancies such as multiple myeloma. However, understanding the biology of this extravascular tissue is imperative to developing better targeted therapy. Here, a mouse model is used to demonstrate that the arteriolar and venous vasculatures are physiologically different. Expression of the receptor Tie2 (tyrosine kinase with immunoglobulin and EGF homology domains) was seen predominantly in the arteriolar vessels. Furthermore, endocytosis of the functional endothelial marker acetylated low-density lipoprotein was more pronounced in the marrow sinusoids and veins but not the arterioles. These results suggest that the bone marrow vasculature is functionally heterogeneous. Recognizing this heterogeneity, studies should be undertaken to determine what types of vessels increase in disease states such as multiple myeloma. Understanding this heterogeneity and how disease affects specific types of blood vessels could allow the development of better targeted therapy to treat marrow disorders. See p 1910.
